CR20180080A - Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas - Google Patents

Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas

Info

Publication number
CR20180080A
CR20180080A CR20180080A CR20180080A CR20180080A CR 20180080 A CR20180080 A CR 20180080A CR 20180080 A CR20180080 A CR 20180080A CR 20180080 A CR20180080 A CR 20180080A CR 20180080 A CR20180080 A CR 20180080A
Authority
CR
Costa Rica
Prior art keywords
combinations
antibody
same
modulator
tlr4 modulator
Prior art date
Application number
CR20180080A
Other languages
English (en)
Inventor
Niranjan Yanamandra
Hua-Xin Gao
Yufeng Li
Christopher John; Francis
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CR20180080A publication Critical patent/CR20180080A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en este documento combinaciones de un modulador de OX40 y un modulador de TLR4, sus composiciones farmacéuticas, sus usos y métodos de tratamiento que comprenden administrar dicha combinación, incluyendo sus usos en el cáncer
CR20180080A 2015-08-06 2016-06-03 Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas CR20180080A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562201828P 2015-08-06 2015-08-06
US201562247488P 2015-10-28 2015-10-28
US201662300400P 2016-02-26 2016-02-26
US201662322906P 2016-04-15 2016-04-15
PCT/IB2016/053285 WO2017021791A1 (en) 2015-08-06 2016-06-03 Combinations of an ox40 antibody and a tlr4 modulator and uses thereof

Publications (1)

Publication Number Publication Date
CR20180080A true CR20180080A (es) 2018-04-02

Family

ID=56131579

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180080A CR20180080A (es) 2015-08-06 2016-06-03 Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas

Country Status (21)

Country Link
US (2) US20170275371A1 (es)
EP (1) EP3331560A1 (es)
JP (2) JP2018525378A (es)
KR (1) KR20180032641A (es)
CN (1) CN108025073A (es)
AU (1) AU2016304401B2 (es)
BR (1) BR112018002530A2 (es)
CA (1) CA2994910A1 (es)
CL (1) CL2018000303A1 (es)
CO (1) CO2018001238A2 (es)
CR (1) CR20180080A (es)
DO (1) DOP2018000034A (es)
EA (1) EA201890457A1 (es)
HK (1) HK1249410A1 (es)
IL (1) IL257067A (es)
MA (1) MA43556A (es)
MX (1) MX2018001515A (es)
PH (1) PH12018500254A1 (es)
TW (1) TW201716084A (es)
WO (1) WO2017021791A1 (es)
ZA (1) ZA201800468B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
CN115317603A (zh) 2016-07-07 2022-11-11 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
WO2019133647A1 (en) * 2017-12-29 2019-07-04 Thevax Genetics Vaccine Co., Ltd. Combination of a fusion protein vaccine with anti-ox40 antibody for use in eliciting antigen-specific immune responses
WO2020030570A1 (en) * 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN113891747A (zh) * 2019-05-15 2022-01-04 郑州威瑞生物技术有限公司 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法
JPWO2022102652A1 (es) * 2020-11-11 2022-05-19

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
CN1606446A (zh) 2000-05-19 2005-04-13 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
ES2261453T3 (es) 2000-08-04 2006-11-16 Corixa Corporation Nuevos compuestos inmunoefectores.
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
CA2511538C (en) * 2002-12-30 2013-11-26 3M Innovative Properties Company Immunostimulatory combinations
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
NZ629913A (en) 2010-08-23 2016-01-29 Univ Texas Anti-ox40 antibodies and methods of using the same
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
RU2562874C1 (ru) * 2011-08-23 2015-09-10 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Антитела против ох40 и способы их применения
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
CA2934028A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Also Published As

Publication number Publication date
US20190338042A1 (en) 2019-11-07
CL2018000303A1 (es) 2018-07-06
ZA201800468B (en) 2019-07-31
MA43556A (fr) 2021-03-24
AU2016304401A1 (en) 2018-02-15
MX2018001515A (es) 2018-03-15
IL257067A (en) 2018-03-29
EA201890457A1 (ru) 2018-09-28
BR112018002530A2 (pt) 2018-09-25
EP3331560A1 (en) 2018-06-13
WO2017021791A1 (en) 2017-02-09
CO2018001238A2 (es) 2018-05-10
TW201716084A (zh) 2017-05-16
JP2021121622A (ja) 2021-08-26
KR20180032641A (ko) 2018-03-30
JP2018525378A (ja) 2018-09-06
AU2016304401B2 (en) 2019-05-16
US20170275371A1 (en) 2017-09-28
PH12018500254A1 (en) 2018-08-13
HK1249410A1 (zh) 2018-11-02
DOP2018000034A (es) 2018-10-31
CN108025073A (zh) 2018-05-11
CA2994910A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
AR106582A1 (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CL2016002971A1 (es) Combinación.
CR20160425A (es) Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
CO2017002472A2 (es) Formulación de acetato de abiraterona
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
DOP2017000260A (es) Piroglutamato de vortioxetina
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b